Literature DB >> 24302216

Interventional cardiology: does an optimal antithrombotic regimen for PCI exist?

A Michael Lincoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24302216     DOI： 10.1038/nrcardio.2013.177

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

2.  Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.

Authors:  Roxana Mehran; Stuart Pocock; Eugenia Nikolsky; George D Dangas; Tim Clayton; Bimmer E Claessen; Adriano Caixeta; Frederick Feit; Steven V Manoukian; Harvey White; Michel Bertrand; E Magnus Ohman; Helen Parise; Alexandra J Lansky; A Michael Lincoff; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2011-06       Impact factor: 11.195

3.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

Authors:  Giuseppe De Luca; Harry Suryapranata; Gregg W Stone; David Antoniucci; James E Tcheng; Franz-Josef Neumann; Frans Van de Werf; Elliott M Antman; Eric J Topol
Journal:  JAMA       Date:  2005-04-13       Impact factor: 56.272

4.  Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry).

Authors:  Phillip A Horwitz; Jesse A Berlin; William H Sauer; Warren K Laskey; Ronald J Krone; Stephen E Kimmel
Journal:  Am J Cardiol       Date:  2003-04-01       Impact factor: 2.778

5.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

6.  Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

Authors:  Jung-Won Suh; Roxana Mehran; Bimmer E Claessen; Ke Xu; Usman Baber; George Dangas; Helen Parise; Alexandra J Lansky; Bernhard Witzenbichler; Cindy L Grines; Giulio Guagliumi; Ran Kornowski; Jochen Wöhrle; Dariusz Dudek; Giora Weisz; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2011-10-18       Impact factor: 24.094

7.  Bivalirudin for patients with acute coronary syndromes.

Authors:  Gregg W Stone; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; Stuart J Pocock; James H Ware; Frederick Feit; Antonio Colombo; Philip E Aylward; Angel R Cequier; Harald Darius; Walter Desmet; Ramin Ebrahimi; Martial Hamon; Lars H Rasmussen; Hans-Jürgen Rupprecht; James Hoekstra; Roxana Mehran; E Magnus Ohman
Journal:  N Engl J Med       Date:  2006-11-23       Impact factor: 91.245

8.  Bivalirudin during primary PCI in acute myocardial infarction.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Ajay J Kirtane; Helen Parise; Roxana Mehran
Journal:  N Engl J Med       Date:  2008-05-22       Impact factor: 91.245

9.  Early versus delayed, provisional eptifibatide in acute coronary syndromes.

Authors:  Robert P Giugliano; Jennifer A White; Christoph Bode; Paul W Armstrong; Gilles Montalescot; Basil S Lewis; Arnoud van 't Hof; Lisa G Berdan; Kerry L Lee; John T Strony; Steven Hildemann; Enrico Veltri; Frans Van de Werf; Eugene Braunwald; Robert A Harrington; Robert M Califf; L Kristin Newby
Journal:  N Engl J Med       Date:  2009-03-30       Impact factor: 91.245

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.